We believe we can empower people to improve and change their diet, lifestyle and health.

Gelesis is a biotechnology company developing a novel category of therapies for GI-related chronic diseases.

The Gelesis portfolio includes a product for obesity and overweight and a pipeline with potential therapies for Non-alcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH), Type 2 diabetes and Chronic Idiopathic Constipation (CIC).

Packaging shown for representation purposes only. Actual packaging design may vary. Plenity is not yet available for sale.

PLENITY is indicated to aid in weight management in adults who are overweight or obese and have a body mass index (BMI) of 25 to 40 kg/m² when combined with diet and exercise.

In clinical trials, side effects with PLENITY were similar to placebo (sugar pill). The most common side effects were fullness, bloating, flatulence, and/or abdominal pain. Instructions for use

“We are thrilled to be able to bring this new approach to the millions of people looking for a safe, validated and convenient approach to manage their weight without surgery or stimulants.”

A novel hydrogel technology platform

We are developing a new category of potential therapies for GI-related chronic diseases.


At Gelesis, we believe that the GI system holds the key to many of the world’s largest epidemics.


By targeting the GI pathway, Gelesis has the potential to transform how chronic diseases are treated.


The Gelesis team is composed of a multi-disciplinary innovative group of leaders with expertise in medicine, materials sciences, manufacturing and commercialization.

The proprietary Gelesis platform is the first and only superabsorbent hydrogel made exclusively from naturally-derived building blocks.

Stay up to date with Gelesis innovations


Gelesis is conducting a proof-of-concept study for its second candidate, Gelesis200, which is designed to address weight loss and glycemic control in patients with type 2 diabetes and prediabetes.